Can Biomarkers Be Used to Identify Patients Who Are Most Likely to Benefit from Adenosine-Pathway Targeted Cancer Immunotherapy?
Time: 12:10 pm
day: Day One
• Discussing the role of adenosine in the tumor microenvironment
• Divulging biomarkers as surrogates for the presence of adenosine
• Highlighting the A2AR as a biomarker for response to inupadenant in iTeos clinical trials